AZD6765 for Treatment Resistant Depression

Phase 2

Completed

• Conditions: Depression

• Registration Number: NCT00491686
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2007-06-25
• Study First Submitted QC: 2007-06-25
• Study First Posted: 2007-06-26
• Study Start: 2007-07
• Primary Completion: 2007-11
• Study Completion: 2007-11
• Status Verified: 2011-01
• Last Update Submitted: 2011-01-20
• Last Update Posted: 2011-01-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

• Diagnosis of Depression
• Inadequate response to an adequate course of antidepressants

Exclusion Criteria

• Psychiatric disorder other than depression
• Pregnancy or lactation
• Current diagnosis of cancer

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
The primary objective is to determine whether an antidepressant effect can be achieved in patients with Treatment Resistant Depression determined by a change from baseline in the MADRS total score.	Change from Baseline

Secondary Outcome Measures

Name	Time	Method
The secondary objective is to assess the safety and tolerability of AZD6765 as assessed by vital signs, physical examination, clinical laboratory evaluations, ECG's and incidence of adverse events.	each visit; change from baseline

Trial Locations

Locations (1)

Research Site; 🇺🇸 Rockville, Maryland, United States